Inhaled Corticosteroids for Asthma Management

Introduction to ICS

• Inhaled corticosteroids (ICS) are the most consistently effective long-term control medications at all steps of care for persistent asthma, and they improve asthma control more effectively in both children and adults than any other single long-term control medication, according to the American Academy of Allergy, Asthma, and Immunology 1, 2

Available ICS Medications

• Beclomethasone dipropionate is available in metered-dose inhalers (MDIs) with both chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA) propellants, as recommended by the Mayo Clinic 3, 4
• Ciclesonide is a newer ICS with potential for fewer local side effects, as noted by the Mayo Clinic 3
• Flunisolide is available in MDI formulation, according to the Mayo Clinic 3, 4
• Mometasone is available in DPI formulation, as recommended by the Mayo Clinic 3, 4
• Triamcinolone acetonide is available in MDI formulation, according to the Mayo Clinic 3, 4

Delivery Devices for ICS

• Metered-dose inhalers (MDIs) can be used with spacers or valved holding chambers to improve delivery, particularly beneficial for children and elderly patients, as suggested by the American Academy of Allergy, Asthma, and Immunology 5
• Dry powder inhalers (DPIs) require sufficient inspiratory flow (may not be suitable for children under 4 years), according to the American Academy of Allergy, Asthma, and Immunology 5
• Breath-actuated MDIs may be useful for patients unable to coordinate inhalation and actuation, as recommended by the American Academy of Allergy, Asthma, and Immunology 5

Role in Asthma Management

• The American Thoracic Society recommends a stepwise approach to ICS use, with low-dose ICS as the preferred controller treatment for mild persistent asthma 6
• The National Asthma Education and Prevention Program suggests that medium-dose ICS or low-dose ICS plus long-acting beta-agonist (LABA) is recommended for moderate persistent asthma, as supported by the American Journal of Respiratory and Critical Care Medicine 7, 8
• High-dose ICS plus LABA, with consideration of add-on biologics like omalizumab, is recommended for severe persistent asthma, according to the American Journal of Respiratory and Critical Care Medicine 7, 8

Efficacy and Benefits

• ICS reduce airway hyperresponsiveness, inhibit inflammatory cell migration and activation, and block late-phase reaction to allergens, as reported by the American Academy of Allergy, Asthma, and Immunology 1, 2
• ICS are more effective than leukotriene receptor antagonists (LTRAs) or other single long-term control medications, according to the American Academy of Allergy, Asthma, and Immunology 1, 9

Safety Considerations

• Local effects of ICS include oral candidiasis, hoarseness, and dysphonia, as noted by the American Academy of Allergy, Asthma, and Immunology 1
• Most side effects are dose-dependent and can be minimized by using spacers, proper inhaler technique, and mouth rinsing after use, as recommended by the American Academy of Allergy, Asthma, and Immunology 5

Comparative Potency

• The DICE study established a rank order of systemic effect potency: flunisolide (1), triamcinolone (1.19:1), beclomethasone (1.69:1), fluticasone DPI (2.08:1), budesonide DPI (3.45:1), and fluticasone CFC (8.33:1), as reported by the Journal of Allergy and Clinical Immunology 10

Combination Therapy

• The American Academy of Allergy, Asthma, and Immunology recommends that LABAs should never be used as monotherapy for asthma and should always be prescribed with an ICS 1

Asthma Management with Inhaled Corticosteroids

Introduction to Asthma Treatment

• The Global Initiative for Asthma (GINA) recommends that all adults and adolescents with asthma receive inhaled corticosteroid (ICS)-containing medication, with a focus on two primary domains: current asthma control and future risk reduction 11

Stepwise Treatment Approach

• For Step 1 (intermittent asthma), the preferred treatment is as-needed low-dose ICS-formoterol, according to the American Academy of Allergy, Asthma, and Immunology 12, 13
• For Step 2 (mild persistent asthma), the preferred treatment is as-needed low-dose ICS-formoterol or daily low-dose ICS, as recommended by the American College of Allergy, Asthma, and Immunology 12, 13
• For Step 3 (moderate persistent asthma), the preferred treatment is low-dose ICS-formoterol daily plus as-needed ICS-formoterol, based on guidelines from the American Thoracic Society 12, 13

Add-on Therapies

• For patients with moderate to severe persistent asthma, adding a leukotriene modifier, such as montelukast, can be considered as an alternative second-line treatment, according to the American Academy of Family Physicians 14
• Omalizumab (anti-IgE) is indicated for patients ≥12 years with moderate to severe persistent asthma inadequately controlled with ICS, with a positive skin test or RAST to perennial aeroallergen, as recommended by the American College of Allergy, Asthma, and Immunology 15, 16

Essential Adjunctive Measures

• Patient education and self-management support, written asthma action plan, environmental control, management of comorbid conditions, inhaler technique assessment and training, and adherence monitoring are mandatory at every step, according to the American Thoracic Society 15, 11

Safety Considerations

• LABAs should never be used as monotherapy for asthma, and should always be combined with ICS, as recommended by the American College of Chest Physicians 15, 16
• Formoterol has rapid onset of action suitable for reliever therapy, while salmeterol has delayed onset and should not be used for SMART strategy, according to the American Academy of Allergy, Asthma, and Immunology 12, 13

Asthma Management Guidelines

Inhaled Corticosteroid Selection and Laboratory Tests

• The American Academy of Family Physicians recommends that long-acting beta2-agonists (LABAs) should never be prescribed as monotherapy for asthma, as this is associated with an increased risk of asthma-related death, and should always be combined with inhaled corticosteroids (ICS) to mitigate this risk 17
• For patients with moderate to severe asthma, the American Academy of Allergy, Asthma, and Immunology suggests that low-to-medium-dose ICS plus leukotriene modifier (montelukast) is an alternative, though inferior to ICS/LABA for patients ≥12 years 17
• The American Academy of Allergy, Asthma, and Immunology recommends that low-to-medium-dose ICS plus theophylline is the least preferred option due to its side effect profile and the need for serum monitoring 18

Laboratory Tests and Monitoring

• The American Academy of Allergy, Asthma, and Immunology suggests that bone densitometry (DEXA scan) should be used to assess for osteoporosis risk, particularly in perimenopausal women, for patients on high-dose ICS (>1 year duration) or frequent oral corticosteroid courses 19
• The American Academy of Allergy, Asthma, and Immunology recommends that slit-lamp eye examination should be used to screen for posterior subcapsular cataracts for patients on high-dose ICS (>1 year duration) or frequent oral corticosteroid courses 19
• The American Academy of Allergy, Asthma, and Immunology suggests that morning plasma cortisol or 24-hour urinary cortisol should be used if there is clinical concern for hypothalamic-pituitary-adrenal (HPA) axis suppression, though this is rare with inhaled therapy 19, 20
• The American Academy of Allergy, Asthma, and Immunology recommends that serum theophylline concentration must be monitored if theophylline is added to ICS therapy, maintaining levels between 5-15 mcg/mL 18

Treatment Algorithm

• The American Academy of Allergy, Asthma, and Immunology suggests that treatment should be stepped up if inadequate control is achieved, and stepped down once control is achieved for 2-4 months to minimize adverse effects 18, 19
• The American Academy of Family Physicians recommends that short-acting beta2-agonist (SABA) use should be reassessed if it exceeds 2 days/week, as this indicates inadequate control requiring treatment intensification 17

First-Line Inhaled Corticosteroid for Persistent Asthma

Recommended Starting Regimens

• The National Asthma Education and Prevention Program (NAEPP) guidelines recommend daily low-dose inhaled corticosteroids (ICS) as the preferred Step 2 treatment for persistent asthma in patients aged 5 years and older, with low-dose fluticasone propionate (100-250 mcg/day) or budesonide (200-400 mcg/day) administered twice daily providing 80-90% of maximum therapeutic benefit at these doses with minimal systemic adverse effects 21
• For children aged 5-11 years, low-dose ICS at age-appropriate dosing (e.g., fluticasone 100 mcg twice daily) is recommended 21

When to Step Up Therapy

• The preferred step-up approach is adding a long-acting beta-agonist (LABA) to low-dose ICS rather than increasing ICS dose alone, as this combination provides greater improvement in lung function, symptoms, and exacerbation reduction than doubling ICS dose 21, 22
• LABAs must never be used as monotherapy for asthma, as this increases risk of severe exacerbations and asthma-related deaths, and must always be combined with ICS in a single inhaler or as separate inhalers 21, 23

Alternative First-Line Options

• For patients ≥12 years with mild persistent asthma who may have adherence concerns with daily therapy, as-needed low-dose ICS-formoterol used concomitantly with short-acting beta-agonist (SABA) is an acceptable alternative to daily low-dose ICS 21, 23

Common Pitfalls to Avoid

• SABA use >2 days/week for symptom relief (excluding exercise prevention) indicates inadequate control requiring treatment intensification 21

Step-Down Strategy

• Once asthma control is sustained for 2-4 months, therapy should be stepped down to the minimum dose required to maintain control, and continue monitoring for at least 3 months of stable control before considering further dose reduction 21

First‑Line Inhaled Corticosteroid Therapy for Persistent Asthma

Preferred First‑Line Regimens (Adults ≥ 12 years)

Preferred First‑Line Regimens (Children)

Monitoring and Treatment Adjustment

Step‑Up Therapy Indicators and Approaches (All Ages)

Safety Considerations for LABA Use

Alternative Controllers (Least Preferred)

Common Pitfalls (Avoiding Unnecessary Dose Escalation)